ReviewHematology/oncology clinics of North America2017
CD30
Review in Hematology/oncology clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Diffuse CD30-Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges.Journal of cutaneous pathology · 2026Article
- Morphologic mimicry of cutaneous T-cell lymphoma as classic Hodgkin lymphoma-a case report.Journal of hematopathology · 2026Article
- Angiogenesis and lymphangiogenesis in primary cutaneous lymphomas: a narrative review.Clinical and experimental medicine · 2025Review
- Retrospective Evaluation of Clinical and Follow-Up Outcomes in Primary Cutaneous CD30Turkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism.Cancers · 2025Review
- Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.Journal of clinical medicine · 2024Review
- Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.BMJ case reports · 2021Article
- Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report.Journal of central nervous system disease · 2021Article
- Man with recurrent necrotic papules.JAAD case reports · 2020Article
- Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.Current hematologic malignancy reports · 2020Review
- Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.Current hematologic malignancy reports · 2020Review
- Ulcerated nodules in a sporotrichoid distribution.JAAD case reports · 2019Article
- Angiodestructive lymphomatoid papulosis lasting more than 45 years.JAAD case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Primary cutaneous CD30
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.